Genomic Health Announces Study Confirming Prognostic Value Of Oncotype DX(R) Recurren

[News]

Genomic Health, Inc. (Nasdaq: GHDX) announced results of a multi-center Japanese study demonstrating that the Oncotype DX breast cancer assay had significant prognostic value in Japanese women with estrogen receptor-positive early-stage breast cancer. Oncotype DX identified a large portion of patients in Japan who had estrogen receptor-positive early-stage breast cancer as having a low likelihood of distant recurrence.

More... (http://www.medicalnewstoday.com/articles/146743.php)